CatalystMarker
← board

BFRG

distress 6/10 · elevated risk
$0.63-1%today-62% from 52w high
bullfrogai.com9 employeesFounded 2017Gaithersburg, MDHealth Information Services
Lead: pancreatic cancer · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$5M
Runway
1.0 yrs
Shares 1y
+84%

Price & events

-23.1% over 6M
$0.46$1.07$1.68Jan 26Apr 26Jul 26417.6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
-0.3%
1W
-4.8%
1M
-25.2%
3M
-12.7%
6M
-59.4%
1Y
-80.1%
2Y
5Y
-90.3%
All

Overview

Market Cap
$11.68M
Volume
28.61K
52 Week Range
$0.46 – $1.68
Total Shares
18.54M
Float Shares
16.11M
Short %
1.44%
% Held by Insiders
13.16%
% Held by Institutions
2.94%
RVOL
0.16x
Beta
-2.81

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 3

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 18,541,651 · 0 offerings/1y · 0 PIPEs
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $ · analysts
  • no recent rating changes

Competitors — pancreatic cancer

  • LLYELI LILLY & Co$1094.4B · D3
  • RVMDRevolution Medicines, Inc.$40.3B · D1
  • JAZZJazz Pharmaceuticals plc$15.7B · D0
  • IBRXImmunityBio, Inc.$7.8B · D5
  • TNGXTango Therapeutics, Inc.$4.0B · D5
  • MNPRMonopar Therapeutics$687M · D1
  • IMRXImmuneering Corp$112M · D3
  • RNXTRenovoRx, Inc.$39M · D5
  • SLXNSilexion Therapeutics Corp$10M · D6
  • AZNASTRAZENECA PLC · D3

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.